<?xml version='1.0' encoding='UTF-8'?><!DOCTYPE collection SYSTEM 'BioC.dtd'>
<collection>
  <source>SourceData</source>
  <date>00000000</date>
  <key>sourcedata.key</key>
  <document>
    <id>5048365 Figure_1-A</id>
    <infon key="sourcedata_document">2261</infon>
    <infon key="doi">10.15252/emmm.201505971</infon>
    <infon key="pmc_id">5048365</infon>
    <infon key="figure">Figure 1-A</infon>
    <infon key="sourcedata_figure_dir">Figure_1-A</infon>
    <passage>
      <offset>0</offset>
      <text>(A) Pearson correlation between ZEB1 and MITF mRNA expression in 61 melanomacell lines available through the CCLE.</text>
    </passage>
  </document>
  <document>
    <id>5048365 Figure_1-B</id>
    <infon key="sourcedata_document">2261</infon>
    <infon key="doi">10.15252/emmm.201505971</infon>
    <infon key="pmc_id">5048365</infon>
    <infon key="figure">Figure 1-B</infon>
    <infon key="sourcedata_figure_dir">Figure_1-B</infon>
    <passage>
      <offset>0</offset>
      <text>(B) ZEB1, ZEB2, TWIST1 and MITF expression in a panel of BRAFV600-mutated melanomacells assessed by Western blot. GLO and C-09.10cells are patient-derived short-term cultures. Actin was used as a loading control.</text>
    </passage>
  </document>
  <document>
    <id>5048365 Figure_1-C</id>
    <infon key="sourcedata_document">2261</infon>
    <infon key="doi">10.15252/emmm.201505971</infon>
    <infon key="pmc_id">5048365</infon>
    <infon key="figure">Figure 1-C</infon>
    <infon key="sourcedata_figure_dir">Figure_1-C</infon>
    <passage>
      <offset>0</offset>
      <text>(C) Quantitative PCR analyses of ZEB1, ZEB2, TWIST1and MITF in the same panel of cell lines. mRNA expression levels are represented relatively to C-09.10 cells, in which the levels were arbitrarily fixed at 1 (n=3, mean &#177; SD). The dotted line separates ZEB1high (left) and ZEB1low (right) cell lines.</text>
    </passage>
  </document>
  <document>
    <id>5048365 Figure_1-D</id>
    <infon key="sourcedata_document">2261</infon>
    <infon key="doi">10.15252/emmm.201505971</infon>
    <infon key="pmc_id">5048365</infon>
    <infon key="figure">Figure 1-D</infon>
    <infon key="sourcedata_figure_dir">Figure_1-D</infon>
    <passage>
      <offset>0</offset>
      <text>(D) Tukey box plot of ZEB1, ZEB2, TWIST1, and MITF mRNA expression according to the IC50 of the drug (&#181;M) administered (BRAFi/MEKi), in melanoma cell lines from the CCLE (n=28) (Student's t-Test). High ZEB1, low ZEB2, and low MITF expression levels were correlated with BRAFi (PLX4720) and MEKi (AZD6244) resistance. PLX4720 is an analog of PLX4032.</text>
    </passage>
  </document>
  <document>
    <id>5048365 Figure_1-E</id>
    <infon key="sourcedata_document">2261</infon>
    <infon key="doi">10.15252/emmm.201505971</infon>
    <infon key="pmc_id">5048365</infon>
    <infon key="figure">Figure 1-E</infon>
    <infon key="sourcedata_figure_dir">Figure_1-E</infon>
    <passage>
      <offset>0</offset>
      <text>(E) IC50 values of PLX4032 (&#181;M) in the panel of BRAFV600 melanoma cells as determined by ATP assay (n=3, mean &#177; SD). For SKMEL24 and WM793, IC50 was &gt;8&#181;M.</text>
    </passage>
  </document>
  <document>
    <id>5048365 Figure_2-A</id>
    <infon key="sourcedata_document">2261</infon>
    <infon key="doi">10.15252/emmm.201505971</infon>
    <infon key="pmc_id">5048365</infon>
    <infon key="figure">Figure 2-A</infon>
    <infon key="sourcedata_figure_dir">Figure_2-A</infon>
    <passage>
      <offset>0</offset>
      <text>(A) Pearson correlation between ZEB1 and MITF mRNA expression levels in 467 melanoma tumors from TCGA data set.</text>
    </passage>
  </document>
  <document>
    <id>5048365 Figure_2-B</id>
    <infon key="sourcedata_document">2261</infon>
    <infon key="doi">10.15252/emmm.201505971</infon>
    <infon key="pmc_id">5048365</infon>
    <infon key="figure">Figure 2-B</infon>
    <infon key="sourcedata_figure_dir">Figure_2-B</infon>
    <passage>
      <offset>0</offset>
      <text>(B) Representative pictures of ZEB1 and MITF immunostaining in primary melanomas. Scale bar = 40 &#181;m. The aberrant activation of ZEB1 in melanomas is correlated with a MITFlow phenotype.</text>
    </passage>
  </document>
  <document>
    <id>5048365 Figure_2-C-D</id>
    <infon key="sourcedata_document">2261</infon>
    <infon key="doi">10.15252/emmm.201505971</infon>
    <infon key="pmc_id">5048365</infon>
    <infon key="figure">Figure 2-C-D</infon>
    <infon key="sourcedata_figure_dir">Figure_2-C-D</infon>
    <passage>
      <offset>0</offset>
      <text>(C) Representative pictures of ZEB1 immunostaining in BRAFV600 tumors from patients, classified in ZEB1 high, int and low subgroups, based on the intensity of ZEB1 staining and on the percentage of cells positive for ZEB1. Scale bar = 80 &#181;m. (D) Pie charts representing the distribution of ZEB1 alone (upper part), or ZEB1 and TWIST1 (lower part) immunohistochemistry staining in tumors according to their initial response to vemurafenib +/- cobimetinib treatment. ZEB1 +/- TWIST1 levels are higher in MAPKi primary resistant melanomas (initial non-responders) compared to tumors that initially respond to treatment (n=70, Fisher's exact test).</text>
    </passage>
  </document>
  <document>
    <id>5048365 Figure_2-E</id>
    <infon key="sourcedata_document">2261</infon>
    <infon key="doi">10.15252/emmm.201505971</infon>
    <infon key="pmc_id">5048365</infon>
    <infon key="figure">Figure 2-E</infon>
    <infon key="sourcedata_figure_dir">Figure_2-E</infon>
    <passage>
      <offset>0</offset>
      <text>(E) Representative pictures of ZEB1 and MITF immunostainings, before and after vemurafenib treatment, in the tumor from patient 1, exhibiting primary resistance to BRAFi. Scale bar = 80 &#181;m. Right: Magnification of MITFhigh and MITFlow clones in the resistant tumor under treatment. Arrows indicate endothelial and stromal cells that also show positive staining for ZEB1, besides tumor cells.</text>
    </passage>
  </document>
  <document>
    <id>5048365 Figure_3-A</id>
    <infon key="sourcedata_document">2261</infon>
    <infon key="doi">10.15252/emmm.201505971</infon>
    <infon key="pmc_id">5048365</infon>
    <infon key="figure">Figure 3-A</infon>
    <infon key="sourcedata_figure_dir">Figure_3-A</infon>
    <passage>
      <offset>0</offset>
      <text>(A) PLX4032 IC50 (&#181;M) of sensitive A375 and SKMEL5 and resistant (A375-R, SKMEL5-R) cell lines, as well as of GOKA and ESPcells, two BRAFi-resistant patient-derived short-term cultures, as determined by ATP assay (n=3, mean &#177; SD). For ESP, IC50 was &gt;8&#181;M.</text>
    </passage>
  </document>
  <document>
    <id>5048365 Figure_3-B</id>
    <infon key="sourcedata_document">2261</infon>
    <infon key="doi">10.15252/emmm.201505971</infon>
    <infon key="pmc_id">5048365</infon>
    <infon key="figure">Figure 3-B</infon>
    <infon key="sourcedata_figure_dir">Figure_3-B</infon>
    <passage>
      <offset>0</offset>
      <text>(B) Western blot analyses of ZEB1, TWIST1 and FRA1 in A375-R and SKMEL5-R versus the parental naive cells, and in GOKA and ESP cells. GAPDH was used as a loading control.</text>
    </passage>
  </document>
  <document>
    <id>5048365 Figure_3-C</id>
    <infon key="sourcedata_document">2261</infon>
    <infon key="doi">10.15252/emmm.201505971</infon>
    <infon key="pmc_id">5048365</infon>
    <infon key="figure">Figure 3-C</infon>
    <infon key="sourcedata_figure_dir">Figure_3-C</infon>
    <passage>
      <offset>0</offset>
      <text>(C) Quantitative PCR analyses of ZEB1and MITF in A375-R and SKMEL5-Rversus the parental naive cells, and in GOKA and ESP cells. mRNA expression levels are represented as arbitrary units (a.u). Statistical difference relative to sensitive A375 cells is shown (n=3, mean &#177; SD, Student's t-test).</text>
    </passage>
  </document>
  <document>
    <id>5048365 Figure_3-D</id>
    <infon key="sourcedata_document">2261</infon>
    <infon key="doi">10.15252/emmm.201505971</infon>
    <infon key="pmc_id">5048365</infon>
    <infon key="figure">Figure 3-D</infon>
    <infon key="sourcedata_figure_dir">Figure_3-D</infon>
    <passage>
      <offset>0</offset>
      <text>(D) Representative pictures of ZEB1 and MITF immunostainings in tumors from patients 2, 3 and 4, before and after vemurafenib treatment. Scale bar = 40 &#181;m. For ZEB1 staining in patient 4, the inset shows a magnification. Arrows point at stromal cells (s). All other cells positive for ZEB1 are tumor cells.</text>
    </passage>
  </document>
  <document>
    <id>5048365 Figure_4-A</id>
    <infon key="sourcedata_document">2261</infon>
    <infon key="doi">10.15252/emmm.201505971</infon>
    <infon key="pmc_id">5048365</infon>
    <infon key="figure">Figure 4-A</infon>
    <infon key="sourcedata_figure_dir">Figure_4-A</infon>
    <passage>
      <offset>0</offset>
      <text>(A) A375 cells were infected with retroviruses expressing ZEB1. Western blot analyses of ZEB1 and p75. GAPDH was used as a loading control.</text>
    </passage>
  </document>
  <document>
    <id>5048365 Figure_4-B</id>
    <infon key="sourcedata_document">2261</infon>
    <infon key="doi">10.15252/emmm.201505971</infon>
    <infon key="pmc_id">5048365</infon>
    <infon key="figure">Figure 4-B</infon>
    <infon key="sourcedata_figure_dir">Figure_4-B</infon>
    <passage>
      <offset>0</offset>
      <text>(B) Quantitative PCR analyses of MITF, p75, ABCB5 and JARID1B upon ZEB1 expression. mRNA expression levels are represented relatively to control cells, in which the levels were fixed at 1 (mean &#177; SD, n=3, Student's t-test).</text>
    </passage>
  </document>
  <document>
    <id>5048365 Figure_4-C</id>
    <infon key="sourcedata_document">2261</infon>
    <infon key="doi">10.15252/emmm.201505971</infon>
    <infon key="pmc_id">5048365</infon>
    <infon key="figure">Figure 4-C</infon>
    <infon key="sourcedata_figure_dir">Figure_4-C</infon>
    <passage>
      <offset>0</offset>
      <text>(C) Soft agar colony formation assay upon ZEB1 expression. Scale bar = 200 &#181;m. Histograms represent quantitative analyses (mean &#177; SD, n=3, Student's t-test).</text>
    </passage>
  </document>
  <document>
    <id>5048365 Figure_4-D</id>
    <infon key="sourcedata_document">2261</infon>
    <infon key="doi">10.15252/emmm.201505971</infon>
    <infon key="pmc_id">5048365</infon>
    <infon key="figure">Figure 4-D</infon>
    <infon key="sourcedata_figure_dir">Figure_4-D</infon>
    <passage>
      <offset>0</offset>
      <text>(D) 2 x 106 Control or ZEB1-overexpressing A375 cells were injected subcutaneously into nude mice. The mean tumor volume for 5 mice is represented &#177; SEM (Student's t-test).</text>
    </passage>
  </document>
  <document>
    <id>5048365 Figure_4-E</id>
    <infon key="sourcedata_document">2261</infon>
    <infon key="doi">10.15252/emmm.201505971</infon>
    <infon key="pmc_id">5048365</infon>
    <infon key="figure">Figure 4-E</infon>
    <infon key="sourcedata_figure_dir">Figure_4-E</infon>
    <passage>
      <offset>0</offset>
      <text>(E) Western blot analyses of ZEB1, MITF, P-ERK, and TWIST1 levels in control or ZEB1-expressing cells +/- 150 nM PLX4032 treatment for 24 h. GAPDH was used as a loading control.</text>
    </passage>
  </document>
  <document>
    <id>5048365 Figure_4-F</id>
    <infon key="sourcedata_document">2261</infon>
    <infon key="doi">10.15252/emmm.201505971</infon>
    <infon key="pmc_id">5048365</infon>
    <infon key="figure">Figure 4-F</infon>
    <infon key="sourcedata_figure_dir">Figure_4-F</infon>
    <passage>
      <offset>0</offset>
      <text>(F) FACS analyses of p75 cell surface expression upon ZEB1 overexpression, after 10 days treatment with or without 150 nM PLX4032. Bar chart representing the mean percentage of p75-high, int and low cells from 2 independent experiments (Fisher's Exact Test).</text>
    </passage>
  </document>
  <document>
    <id>5048365 Figure_4-G</id>
    <infon key="sourcedata_document">2261</infon>
    <infon key="doi">10.15252/emmm.201505971</infon>
    <infon key="pmc_id">5048365</infon>
    <infon key="figure">Figure 4-G</infon>
    <infon key="sourcedata_figure_dir">Figure_4-G</infon>
    <passage>
      <offset>0</offset>
      <text>(G) Control or ZEB1-overexpressing A375 cells were transfected with control or p75-siRNA. p75 and MITF expression levels were was analyzed by quantitative PCR after 48 h. mRNA expression levels are represented relatively to control cells transfected with siRNA Control, in which the levels were fixed at 1 (mean &#177; SD, n=2).</text>
    </passage>
  </document>
  <document>
    <id>5048365 Figure_4-H-I</id>
    <infon key="sourcedata_document">2261</infon>
    <infon key="doi">10.15252/emmm.201505971</infon>
    <infon key="pmc_id">5048365</infon>
    <infon key="figure">Figure 4-H-I</infon>
    <infon key="sourcedata_figure_dir">Figure_4-H-I</infon>
    <passage>
      <offset>0</offset>
      <text>(H) Clonogenic assay +/- PLX4032 (150 nM), +/- GDC-0973 (5 nM) treatment for 10 days. The graphs represent the mean number of colonies (&#177; SD) in 3 independent experiments (Student's t-test). (I) Number of weeks of chronic exposure to PLX4032 before emergence of resistance in control or ZEB1-expressing cells (n=3, Student's t-test).</text>
    </passage>
  </document>
  <document>
    <id>5048365 Figure_5-A</id>
    <infon key="sourcedata_document">2261</infon>
    <infon key="doi">10.15252/emmm.201505971</infon>
    <infon key="pmc_id">5048365</infon>
    <infon key="figure">Figure 5-A</infon>
    <infon key="sourcedata_figure_dir">Figure_5-A</infon>
    <passage>
      <offset>0</offset>
      <text>(A) C-09.10 short-term culture cells were infected with retroviruses expressing ZEB1. Western blot analyses of ZEB1 and p75. GAPDH was used as a loading control.</text>
    </passage>
  </document>
  <document>
    <id>5048365 Figure_5-B</id>
    <infon key="sourcedata_document">2261</infon>
    <infon key="doi">10.15252/emmm.201505971</infon>
    <infon key="pmc_id">5048365</infon>
    <infon key="figure">Figure 5-B</infon>
    <infon key="sourcedata_figure_dir">Figure_5-B</infon>
    <passage>
      <offset>0</offset>
      <text>(B) Quantitative PCR analyses of MITF and p75 upon ZEB1 expression. mRNA expression levels are represented relatively to control cells (mean &#177; SD, n=3, Student's t-test).</text>
    </passage>
  </document>
  <document>
    <id>5048365 Figure_5-C</id>
    <infon key="sourcedata_document">2261</infon>
    <infon key="doi">10.15252/emmm.201505971</infon>
    <infon key="pmc_id">5048365</infon>
    <infon key="figure">Figure 5-C</infon>
    <infon key="sourcedata_figure_dir">Figure_5-C</infon>
    <passage>
      <offset>0</offset>
      <text>(C) Soft agar colony formation assay following ZEB1 expression. Scale bar = 200 &#181;m. Histograms represent quantitative analyses (mean &#177; SD, n=3, Student's t-test).</text>
    </passage>
  </document>
  <document>
    <id>5048365 Figure_5-D</id>
    <infon key="sourcedata_document">2261</infon>
    <infon key="doi">10.15252/emmm.201505971</infon>
    <infon key="pmc_id">5048365</infon>
    <infon key="figure">Figure 5-D</infon>
    <infon key="sourcedata_figure_dir">Figure_5-D</infon>
    <passage>
      <offset>0</offset>
      <text>(D) FACS analyses of p75 cell surface expression upon ZEB1 overexpression. Bar chart representing the mean percentage of p75-high, int, low and negative cells from 2 independent experiments (Fisher's exact test).</text>
    </passage>
  </document>
  <document>
    <id>5048365 Figure_5-E</id>
    <infon key="sourcedata_document">2261</infon>
    <infon key="doi">10.15252/emmm.201505971</infon>
    <infon key="pmc_id">5048365</infon>
    <infon key="figure">Figure 5-E</infon>
    <infon key="sourcedata_figure_dir">Figure_5-E</infon>
    <passage>
      <offset>0</offset>
      <text>(E) Clonogenic assay +/- PLX4032 (100 nM) treatment for 10 days. The graph represents the mean number of colonies in 3 independent experiments (Student's t-test).</text>
    </passage>
  </document>
  <document>
    <id>5048365 Figure_6-A</id>
    <infon key="sourcedata_document">2261</infon>
    <infon key="doi">10.15252/emmm.201505971</infon>
    <infon key="pmc_id">5048365</infon>
    <infon key="figure">Figure 6-A</infon>
    <infon key="sourcedata_figure_dir">Figure_6-A</infon>
    <passage>
      <offset>0</offset>
      <text>(A) A375 cells were infected with retroviruses expressing a control or ZEB1-shRNA. Western blot analyses of ZEB1 and p75 upon ZEB1 knock-down. GAPDH was used as a loading control. High and low exposures (exp) for p75 are shown.</text>
    </passage>
  </document>
  <document>
    <id>5048365 Figure_6-B</id>
    <infon key="sourcedata_document">2261</infon>
    <infon key="doi">10.15252/emmm.201505971</infon>
    <infon key="pmc_id">5048365</infon>
    <infon key="figure">Figure 6-B</infon>
    <infon key="sourcedata_figure_dir">Figure_6-B</infon>
    <passage>
      <offset>0</offset>
      <text>(B) Quantitative PCR analyses of MITF, p75, ABCB5 and JARID1B upon ZEB1 knock-down. mRNA expression levels are represented relatively to shRNA control cells (mean &#177; SD, n=3, Student's t-test).</text>
    </passage>
  </document>
  <document>
    <id>5048365 Figure_6-C</id>
    <infon key="sourcedata_document">2261</infon>
    <infon key="doi">10.15252/emmm.201505971</infon>
    <infon key="pmc_id">5048365</infon>
    <infon key="figure">Figure 6-C</infon>
    <infon key="sourcedata_figure_dir">Figure_6-C</infon>
    <passage>
      <offset>0</offset>
      <text>(C) FACS analyses of p75 expression upon ZEB1 knock-down. Bar chart representing the mean percentage of p75-high, int and low cells from 2 independent experiments (Fisher's exact test).</text>
    </passage>
  </document>
  <document>
    <id>5048365 Figure_6-D</id>
    <infon key="sourcedata_document">2261</infon>
    <infon key="doi">10.15252/emmm.201505971</infon>
    <infon key="pmc_id">5048365</infon>
    <infon key="figure">Figure 6-D</infon>
    <infon key="sourcedata_figure_dir">Figure_6-D</infon>
    <passage>
      <offset>0</offset>
      <text>(D) Soft agar colony formation assay upon ZEB1 knock-down. Scale bar = 200 &#181;m. Histograms represent quantitative analyses (mean &#177; SD, n=3, Student's t-test).</text>
    </passage>
  </document>
  <document>
    <id>5048365 Figure_6-E</id>
    <infon key="sourcedata_document">2261</infon>
    <infon key="doi">10.15252/emmm.201505971</infon>
    <infon key="pmc_id">5048365</infon>
    <infon key="figure">Figure 6-E</infon>
    <infon key="sourcedata_figure_dir">Figure_6-E</infon>
    <passage>
      <offset>0</offset>
      <text>(E) 2 x 106 Control or ZEB1-shRNA A375 cells were injected subcutaneously into nude mice. The mean tumor volume for 5 mice is represented (&#177; SEM). (Student's t-test).</text>
    </passage>
  </document>
  <document>
    <id>5048365 Figure_6-F</id>
    <infon key="sourcedata_document">2261</infon>
    <infon key="doi">10.15252/emmm.201505971</infon>
    <infon key="pmc_id">5048365</infon>
    <infon key="figure">Figure 6-F</infon>
    <infon key="sourcedata_figure_dir">Figure_6-F</infon>
    <passage>
      <offset>0</offset>
      <text>(F) A375 cells were infected with an IPTG-inducible ZEB1-shRNA. Left panel: Western blot analyses of ZEB1 expression &#177; IPTG (100&#181;M) treatment for 6 days. Actin was used as a loading control. Right panel: 2 x 106 IPTG-inducible shRNA-Control or shRNA-ZEB1A375 cells were injected subcutaneously into nude mice. When the tumor reached 5 mm in diameter, ZEB1 expression was silenced by adding IPTG (10 mM) into the drinking water for 20 days. The mean tumor volume for 5 mice is represented (&#177; SEM). (Student's t-test).</text>
    </passage>
  </document>
  <document>
    <id>5048365 Figure_6-G</id>
    <infon key="sourcedata_document">2261</infon>
    <infon key="doi">10.15252/emmm.201505971</infon>
    <infon key="pmc_id">5048365</infon>
    <infon key="figure">Figure 6-G</infon>
    <infon key="sourcedata_figure_dir">Figure_6-G</infon>
    <passage>
      <offset>0</offset>
      <text>(G) SKMEL5 cells expressing an IPTG-inducible ZEB1-shRNA were treated with IPTG (100&#181;M) for 10 days (+IPTG), then IPTG was removed (-IPTG) and ZEB1, MITF and p75 expression levels were analyzed by Western blot and/or quantitative PCR analyses. GAPDH was used as a protein loading control, mRNA expression levels are represented relatively to untreated cells, in which the levels were fixed at 1 (mean &#177; SD, n=2).</text>
    </passage>
  </document>
  <document>
    <id>5048365 Figure_7-A</id>
    <infon key="sourcedata_document">2261</infon>
    <infon key="doi">10.15252/emmm.201505971</infon>
    <infon key="pmc_id">5048365</infon>
    <infon key="figure">Figure 7-A</infon>
    <infon key="sourcedata_figure_dir">Figure_7-A</infon>
    <passage>
      <offset>0</offset>
      <text>(A) Western blot analyses of ZEB1 and P-ERK in shRNA-control or shRNA-ZEB1-expressing A375 cells +/- 150 nM PLX4032 treatment for 24 h. GAPDH was used as a loading control.</text>
    </passage>
  </document>
  <document>
    <id>5048365 Figure_7-B-C</id>
    <infon key="sourcedata_document">2261</infon>
    <infon key="doi">10.15252/emmm.201505971</infon>
    <infon key="pmc_id">5048365</infon>
    <infon key="figure">Figure 7-B-C</infon>
    <infon key="sourcedata_figure_dir">Figure_7-B-C</infon>
    <passage>
      <offset>0</offset>
      <text>(B) Soft agar colony formation assay in A375 cells in the presence or absence of PLX4032 (150 nM). Scale bar = 100 &#181;m. Histograms represent quantitative analyses (mean &#177; SD, n=3, Student's t-test). (C) Number of weeks of chronic exposure to PLX4032 before emergence of resistance in control or shRNA-ZEB1-expressing cells (n=3, Student's t-test).</text>
    </passage>
  </document>
  <document>
    <id>5048365 Figure_7-D</id>
    <infon key="sourcedata_document">2261</infon>
    <infon key="doi">10.15252/emmm.201505971</infon>
    <infon key="pmc_id">5048365</infon>
    <infon key="figure">Figure 7-D</infon>
    <infon key="sourcedata_figure_dir">Figure_7-D</infon>
    <passage>
      <offset>0</offset>
      <text>(D) RPMI7951, A375-R and SKMEL5-R were infected with a retrovirus encoding a constitutive shRNA-ZEB1. Short-term cultures of GOKA and ESP cells, derived from vemurafenib-resistant patients, were infected with a lentivirus encoding an IPTG-inducible shRNA-ZEB1. Western blot analyses showing efficient ZEB1 knock-down in the different models, &#177;IPTG (200&#181;M), &#177;PLX4032 (3&#181;M) as indicated. Induction of cell death was assessed by PARP cleavage. GAPDH or actin were used as loading control.</text>
    </passage>
  </document>
  <document>
    <id>5048365 Figure_7-E</id>
    <infon key="sourcedata_document">2261</infon>
    <infon key="doi">10.15252/emmm.201505971</infon>
    <infon key="pmc_id">5048365</infon>
    <infon key="figure">Figure 7-E</infon>
    <infon key="sourcedata_figure_dir">Figure_7-E</infon>
    <passage>
      <offset>0</offset>
      <text>(E) Clonogenic assays in the presence of 3 &#181;M PLX4032, and with or without IPTG (200 &#181;M) as indicated. The graphs represent the mean number of colonies in 3 independent experiments (Student's t-test).</text>
    </passage>
  </document>
  <document>
    <id>5048365 Figure_7-F</id>
    <infon key="sourcedata_document">2261</infon>
    <infon key="doi">10.15252/emmm.201505971</infon>
    <infon key="pmc_id">5048365</infon>
    <infon key="figure">Figure 7-F</infon>
    <infon key="sourcedata_figure_dir">Figure_7-F</infon>
    <passage>
      <offset>0</offset>
      <text>(F) Western blot analyses of ZEB1, p75 and quantitative PCR analyses of MITF in shRNA-Control or shRNA-ZEB1ESPvemurafenib-resistant patient-derived short-term culture cells. Actin was used as a loading control. mRNA expression levels are represented relatively to control cells (mean &#177; SD, n=3, Student's t-test).</text>
    </passage>
  </document>
  <document>
    <id>5048365 Figure_7-G</id>
    <infon key="sourcedata_document">2261</infon>
    <infon key="doi">10.15252/emmm.201505971</infon>
    <infon key="pmc_id">5048365</infon>
    <infon key="figure">Figure 7-G</infon>
    <infon key="sourcedata_figure_dir">Figure_7-G</infon>
    <passage>
      <offset>0</offset>
      <text>(G) 2,5 x 106 shRNA-Control or shRNA-ZEB1ESPvemurafenib-resistant cells were injected subcutaneously in nude mice. When the tumor reached 5 mm in diameter, ZEB1 expression was silenced by providing mice with IPTG (10 mM) in their drinking water and orally administering vemurafenib (50 mg/kg) daily for 4 weeks. The mean tumor volume for 5 mice is represented (&#177; SEM). (Student's t-test).</text>
    </passage>
  </document>
  <document>
    <id>5048365 Figure_7-H</id>
    <infon key="sourcedata_document">2261</infon>
    <infon key="doi">10.15252/emmm.201505971</infon>
    <infon key="pmc_id">5048365</infon>
    <infon key="figure">Figure 7-H</infon>
    <infon key="sourcedata_figure_dir">Figure_7-H</infon>
    <passage>
      <offset>0</offset>
      <text>(H) Upper part: Western blot analyses of ZEB1 in shRNA-Control (1 to 4) or shRNA-ZEB1 (5 to 8) ESPxenografttumors, showing efficient ZEB1 knock-down directly in the tumors, after IPTG &#177;PLX4032 treatment in vivo. Lower part: Representative pictures of ZEB1 immunostaining in shRNA-Control or shRNA-ZEB1tumors, after IPTG treatment in vivo. Scale bar = 40&#181;m.</text>
    </passage>
  </document>
</collection>
